Skip to main content

UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States

Buy Article:

$51.00 plus tax (Refund Policy)



The efficacy and safety of UVA1 (340–400 nm) phototherapy were established by studies from European countries. Purpose:

Evaluate experience with UVA1 phototherapy for patients with cutaneous diseases in the United States. Methods:

A retrospective analysis of 92 cases of UVA1-treated cutaneous conditions from four medical centers in the United States was performed. Results:

Two-third of the patients showed a fair to good response (26–100% improvement) and one-third of the patients showed a poor response (0–25% improvement). Diseases with a moderate to good response (51–100% improvement) included scleredema adultorum, hand or foot dermatitis, atopic dermatitis, morphea (medium or medium- to high-dose UVA1), systemic sclerosis, and urticaria pigmentosa. Besides tanning, other adverse effects were found in 15% of patients, which include pruritus, erythema, tenderness, and burning sensation. Patients with skin types I–III responded better that those with a darker skin type. Conclusion:

UVA1 phototherapy is a useful and well-tolerated treatment option for a variety of skin conditions.

Keywords: UVA1; phototherapy

Document Type: Research Article


Affiliations: 1: Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA, 2: Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA, 3: Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA and 4: Department of Dermatology, University of Alabama, Birmingham, AL, USA

Publication date: October 1, 2006


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more